Vaxcyte — Third Quarter 2026 Earnings Summary

Vaxcyte reported positive topline data from the OPUS-1 Phase 3 trial for its VAX-31 vaccine candidate, meeting all prespecified primary immunogenicity endpoints in adults aged 50 and older. The company announced plans to submit a Biologics License Application in the first half of 2028, supported by expected results from the OPUS-2 and OPUS-3 trials in early 2027. In October 2026, Vaxcyte completed equity and convertible senior notes offerings that generated approximately $1.1 billion in net proceeds, bringing pro forma cash and investments to roughly $3.4 billion as of September 30, 2026. For the third quarter ended September 30, 2026, the company reported a net loss of $297.1 million, driven primarily by increased research and development expenses related to its PCV programs.